AG2R LA Mondiale Gestion D Actifs Invests $5.77 Million in Boston Scientific Corporation $BSX

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired a new position in Boston Scientific Corporation, purchasing 54,844 shares for approximately $5.77 million in the first quarter.
• Several major investors, including GAMMA Investing LLC and UBS AM, significantly increased their holdings in Boston Scientific, with hedge funds owning 89.07% of the stock.
• Boston Scientific recently reported a 22.8% increase in quarterly revenue year-over-year, and analysts have set a consensus target price of $118.04 for the stock.

AG2R LA Mondiale Gestion D Actifs bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 54,844 shares of the medical equipment provider's stock, valued at approximately $5,773,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. HM Payson & Co. increased its stake in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares in the last quarter. Park Square Financial Group LLC increased its position in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the period. HHM Wealth Advisors LLC increased its position in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after purchasing an additional 103 shares during the period. Rise Advisors LLC increased its position in Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 103 shares during the period. Finally, Forum Financial Management LP increased its position in Boston Scientific by 0.8% in the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after purchasing an additional 112 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BSX. Citigroup reiterated a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Truist Financial lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Barclays lifted their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and an average price target of $118.04.

Boston Scientific Stock Down 1.6%

Shares of BSX traded down $1.63 on Friday, hitting $102.71. The company's stock had a trading volume of 10,541,837 shares, compared to its average volume of 6,378,869. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm's fifty day moving average price is $104.86 and its 200-day moving average price is $102.27. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a market capitalization of $152.19 billion, a price-to-earnings ratio of 61.14, a P/E/G ratio of 2.47 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the firm earned $0.62 EPS. Boston Scientific's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.